Postoperative Sugammadex After COVID-19
General Anesthesia, COVID-19
About this trial
This is an interventional treatment trial for General Anesthesia focused on measuring COVID-19, Postoperative Complications
Eligibility Criteria
Inclusion Criteria: Ages between 19 and 70 Male and Female All ethnicity Patients who are scheduled to take non-emergency abdominal surgery under general anesthesia. Patients who had the diagnosis of covid-19 by PCR, hospitalized, and applied O2 supplement therapy. ASA classification ≤ 3 Patients who had Covid-19 PCR positive within 1 year Patients who had hospitalized by Covid-19, followed by O2 therapy (nasal prong, continuous positive airway pressure (CPAP), ventilator etc.) Patients who hospitalized more than 48 hours after surgery. Patients who had a surgery for more than 1 hour. Exclusion Criteria: Not meeting inclusion criteria Declined to participate Active Covid-19 patients with PCR positive. Patients are under 19 or over 70 years old
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Sugammadex
Neostigmine
sugammadex 2mg/kg
neostigmine 50µg/kg + glycopyrollate 0.01mg/kg